Digital health company ResApp has seen its ResAppDX-EU product receive CE mark certification as a Class IIa medical device.
The product is a smartphone-based diagnostic test for acute paediatric respiratory disease. Most people will develop an acute respiratory tract infection every year and these infections are the most common acute illnesses seen in primary care. Today, acute respiratory disease diagnosis, especially in children, is a complex, subjective process, combining clinical judgement with diagnostic aids such as auscultation with a stethoscope, imaging, blood and sputum tests.
ResAppDx-EU is a mobile software application to be used by clinicians for the diagnosis of lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease and bronchiolitis in infants and children. The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose disease. ResAppDx-EU is a software-only solution that runs on an off-the-shelf smartphone and does not require any additional hardware or accessories.
The CE Mark approval was supported by data collected in ResApp’s Breath Easy paediatric clinical study. The Breath Easy study was a double-blind, prospective study which evaluated the efficacy of ResApp’s cough-based diagnosis algorithms in diagnosing acute respiratory disease in children. Results from the study were recently published in the peer-reviewed journal Respiratory Research.
Tony Keating, CEO and managing director of ResApp said: “We are very excited about receiving our first regulatory approval for ResAppDx-EU, our flagship acute diagnostic product. This is our biggest achievement yet and results from many years of hard work by our dedicated team. For the first time clinicians in Europe will have access to a rapid and accurate diagnostic test for the most commonly seen acute respiratory conditions in children. ResAppDx-EU has the potential to have far-reaching benefits in the healthcare system and we will now rapidly move ahead with our European commercialisation strategy.”
CE Mark certification will facilitate further regulatory submissions in Australia, Canada and Singapore. In April, ResApp submitted a De Novo classification request to the US Food and Drug Administration which is currently pending review.
